Compare Stocks: PMN, ANL, KYTX, and CABA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.82 -3.5%	$12.16	$0.88 ▼ $17.25	$552.80M	1.06	158,975 shs	165,028 shs
CABA Cabaletta Bio	$3.12 -7.7%	$2.92	$1.40 ▼ $4.23	$528.98M	3.3	4.28 million shs	3.23 million shs
KYTX Kyverna Therapeutics	$8.37 -3.1%	$8.20	$3.55 ▼ $13.67	$517.63M	1.93	679,626 shs	524,922 shs
PMN Promis Neurosciences	$13.78 -1.5%	$13.63	$6.27 ▼ $27.40	$123.62M	-0.23	26,811 shs	51,475 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+0.88%	+6.31%	+15.75%	+717.27%
CABA Cabaletta Bio	0.00%	-0.32%	+14.71%	-17.46%	+108.00%
KYTX Kyverna Therapeutics	0.00%	-0.59%	+11.75%	-1.76%	+126.83%
PMN Promis Neurosciences	0.00%	-5.03%	-7.64%	+27.47%	+3.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.82 -3.5%	$12.16	$0.88 ▼ $17.25	$552.80M	1.06	158,975 shs	165,028 shs
CABA Cabaletta Bio	$3.12 -7.7%	$2.92	$1.40 ▼ $4.23	$528.98M	3.3	4.28 million shs	3.23 million shs
KYTX Kyverna Therapeutics	$8.37 -3.1%	$8.20	$3.55 ▼ $13.67	$517.63M	1.93	679,626 shs	524,922 shs
PMN Promis Neurosciences	$13.78 -1.5%	$13.63	$6.27 ▼ $27.40	$123.62M	-0.23	26,811 shs	51,475 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+0.88%	+6.31%	+15.75%	+717.27%
CABA Cabaletta Bio	0.00%	-0.32%	+14.71%	-17.46%	+108.00%
KYTX Kyverna Therapeutics	0.00%	-0.59%	+11.75%	-1.76%	+126.83%
PMN Promis Neurosciences	0.00%	-5.03%	-7.64%	+27.47%	+3.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	75.47% Upside
CABA Cabaletta Bio	2.75	Moderate Buy	$15.33	391.45% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	258.42% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	146.73% Upside

Current Analyst Ratings Breakdown

Latest PMN, ANL, KYTX, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	CABA Cabaletta Bio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/17/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/14/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$18.06M	30.62	N/A	N/A	$5.37 per share	2.57
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.24 per share	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$2.68 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$5.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)

Latest PMN, ANL, KYTX, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	0.65
CABA Cabaletta Bio	N/A	5.79	5.79
KYTX Kyverna Therapeutics	0.15	9.06	9.06
PMN Promis Neurosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
CABA Cabaletta Bio	N/A
KYTX Kyverna Therapeutics	18.08%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
CABA Cabaletta Bio	6.44%
KYTX Kyverna Therapeutics	17.60%
PMN Promis Neurosciences	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	40.00 million	N/A	Not Optionable
CABA Cabaletta Bio	50	169.55 million	158.63 million	Optionable
KYTX Kyverna Therapeutics	96	61.84 million	50.96 million	Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable

PMN, ANL, KYTX, and CABA Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)

August 22, 2026 | theglobeandmail.com

PMN Q3 EPS Forecast Boosted by Brookline Capital Markets

August 21, 2026 | americanbankingnews.com

Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

August 19, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

August 14, 2026 | marketbeat.com

Promis Neurosciences Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 13, 2026 | marketbeat.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | finanznachrichten.de

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 7, 2026 | marketbeat.com

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

August 4, 2026 | marketbeat.com

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum

August 4, 2026 | gurufocus.com

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026 | globenewswire.com

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

July 28, 2026 | benzinga.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026 | markets.businessinsider.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

July 28, 2026 | globenewswire.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | finanznachrichten.de

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

July 27, 2026 | markets.businessinsider.com

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | globenewswire.com

PMN310 cuts Alzheimer oligomers in humans, dodging side effects that limit rival drugs

July 15, 2026 | msn.com

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, ANL, KYTX, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

$13.82 -0.50 (-3.49%)

As of 08/28/2026 04:00 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Cabaletta Bio NASDAQ:CABA

$3.12 -0.26 (-7.69%)

As of 08/28/2026 04:00 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Kyverna Therapeutics NASDAQ:KYTX

$8.37 -0.27 (-3.13%)

As of 08/28/2026 04:00 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Promis Neurosciences NASDAQ:PMN

$13.78 -0.21 (-1.50%)

As of 08/28/2026 04:00 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, ANL, KYTX, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, ANL, KYTX, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, ANL, KYTX, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, ANL, KYTX, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

Cabaletta Bio NASDAQ:CABA

Kyverna Therapeutics NASDAQ:KYTX

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, ANL, KYTX, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, ANL, KYTX, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, ANL, KYTX, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, ANL, KYTX, and CABA Company Descriptions

Adlai Nortye NASDAQ:ANL

Cabaletta Bio NASDAQ:CABA

Kyverna Therapeutics NASDAQ:KYTX

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools